ArticleHealth affairs (Project Hope)2020
Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.
Article in Health affairs (Project Hope), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148206 (Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?Journal of substance abuse treatment · 2022Pooled it
- Thresholds for adjunctive medication usage and probability of initiating injectable naltrexone.Addiction (Abingdon, England) · 2026Trial
- Offering nurse care management for opioid use disorder in primary care: Impact on emergency and hospital utilization in a cluster-randomized implementation trial.Drug and alcohol dependence · 2024Trial
- How do services offered within opioid treatment programs vary based on state methadone policies?Journal of substance use and addiction treatment · 2026Article
- Duration of Medication Use for Opioid Use Disorder and Risk of Postpartum Overdose and Death.JAMA network open · 2026Article
- Reducing Buprenorphine Misinformation as a Strategy to Improve Adoption in Primary Care.Substance use & misuse · 2026Article
- Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder.JAMA psychiatry · 2026Article
- Evaluating the optimal duration of medication treatment for opioid use disorder.Addiction (Abingdon, England) · 2026Article
- Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era.Addictive behaviors · 2026Article
- Differences in buprenorphine initiation and retention for opioid use disorder between primary care and substance use disorder specialty care settings.Journal of substance use and addiction treatment · 2026Article
- Older Age Is Associated With Long-Term Retention in Buprenorphine Treatment for Opioid Use Disorder.Journal of the American Geriatrics Society · 2026Article
- Article
- Buprenorphine Treatment Duration and Adherence Among Youth and Subsequent Health Outcomes.Pediatrics · 2025Article
- The Economic Case for Hospital-Initiated Medications for Opioid Use Disorder in Incarcerated Populations.Journal of general internal medicine · 2025Article
- Perspectives on medication for opioid use disorder (MOUD) access and service delivery among a community sample of people who use opioids in Los Angeles.Journal of substance use and addiction treatment · 2025Article
- States With Substantial Increases In Buprenorphine Uptake Did So With Increased Medicaid Prescribing, 2018-24.Health affairs (Project Hope) · 2025Article
- Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs.JAMA network open · 2025Article
- Substance use patterns among U.S. adults with HIV: identifying priorities for screening and interventions.AIDS care · 2025Article
- Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.Journal of medical Internet research · 2025Article
- Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl.Addiction science & clinical practice · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The optimal, or even minimum, duration of medication treatment for opioid use disorder (OUD) needed to improve long-term outcomes has not been established empirically. As a result, health plans set potentially restrictive treatment standards to guide benefits and payment. To address this gap, we used a National Quality Forum measure for OUD medication treatment duration (180 days) to examine the impact of longer treatment on health care outcomes within a key population of Medicaid enrollees. Compared to buprenorphine discontinuation around the National Quality Forum benchmark (six to nine months), longer treatment (at least fifteen months) was associated with relative reductions in the risk of having all-cause inpatient (-52 percent) and emergency department (-26 percent) use, opioid-related hospital use (-128 percent), overdose events (-173 percent), and opioid prescriptions (-120 percent) and in the rate of prescription opioid use (-124 percent). We argue that these clinical benefits provide a rationale for policies that increase access to longer-term buprenorphine treatment, including lengthening the standards for minimum treatment duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.